Fig 2: Promoter hypomethylation and miR-3655 downregulation contributed to GABRP upregulation in PAAD (A) Correlation analysis between GABRP expression and GABRP methylation; (B) comparison of GABRP promoter methylation level in tumor tissues compared with normal tissues; (C) common miRNAs containing GABRP-binding sequences using miRDB, TargetScan and MirWalk databases; (D) expression of miR-3655 in PAAD tissues compared with normal tissues; (E) low miR-3655 predicts worse survival in PAAD; (F) putative binding site of GABRP 3'-UTR by miR-3655. **, P<0.01; ****, P<0.0001. PAAD, pancreatic adenocarcinoma.

Fig 3: Analysis of genes co-expressed with GABRP in PAAD. The bubble plot for (A) GO-BP, (B) GO-CC and (C) GO-MF and (D) KEGG pathway analysis by GSEA. NES, normalized enrichment score; PAAD, pancreatic adenocarcinoma; GO, Gene ontology; BP, biological process; CC, cellular component; MF, molecular function; KEGG, Kyoto Encyclopedia of Genes and Genomes; GSEA, gene set enrichment analysis; FDR, false discovery rate.

Fig 4: Correlation between GABRP expression and immune infiltration in pancreatic cancer. (A) Association between GABRP expression and immune cell infiltration in PAAD; (B) associations between GABRP gene copy numbers and immune cell infiltration in PAAD. *, P<0.05; **, P<0.01; ***, P<0.001. PAAD, pancreatic adenocarcinoma.

Fig 5: Overexpressed GABRP independently predicts poor OS in PAAD. (A,B) Correlation between GABRP and prognosis of pancreatic cancer in Kaplan-Meier plotter database; (C,D) correlation between GABRP and prognosis of pancreatic cancer in GEPIA2 database. OS, overall survival; PAAD, pancreatic adenocarcinoma.